{"name":"TVAX Biomedical","slug":"tvax-biomedical","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Cancer vaccine plus immune adjuvant","genericName":"Cancer vaccine plus immune adjuvant","slug":"cancer-vaccine-plus-immune-adjuvant","indication":"Other","status":"phase_1"},{"name":"TVI-Brain 1","genericName":"TVI-Brain 1","slug":"tvi-brain-1","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Cancer vaccine plus immune adjuvant","genericName":"Cancer vaccine plus immune adjuvant","slug":"cancer-vaccine-plus-immune-adjuvant","phase":"phase_1","mechanism":"Combines cancer antigens with immune adjuvants to stimulate and enhance the body's immune response against tumor cells.","indications":[],"catalyst":""},{"name":"TVI-Brain 1","genericName":"TVI-Brain 1","slug":"tvi-brain-1","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2025-01-27","type":"trial","source":"globenewswire.com","summary":"Glioblastoma Market, an Area With High Trial Failure And - globenewswire.com","headline":"Glioblastoma Market, an Area With High Trial Failure And","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQaGhILXdYN1Bsc1hScS1CbFZGbm5zMmtyWEZSajE5VDhDWlVBM0txbXFQeC10LW1ra2s4TWE4YzJqdWRRYWM1U0thazNjZ2N6QkozTm9Jbkh5LTRrUllsZzhvT0NZY2VMOUEyUzRCTi1MeFNVSHFZRXQzdEd2WjdYVlVhV2Z5emRWOUxCRnRXOFA?oc=5","date":"2024-11-03","type":"pipeline","source":"siteselection.com","summary":"Public, Private Investment Grew Kansas’ Biotech Sector in 2022 - siteselection.com","headline":"Public, Private Investment Grew Kansas’ Biotech Sector in 2022","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxNZk5kTm1HV0poaEtvVEV3RF91Nm5qQjItX0t0TFp3VDE1VGxwbElZc2R5UjRhZENQamw3QS0xS1JfWFVHT2FmSk5GNzJkMlJoMTlHX3RJc2JObm95NXNJOEs3U1V6NFNPUVBGTDVubmdsTU9Mb2FFNloydUFsUUd0MER5dnMxZEJRcXZrQ053TDN1bEhRaTRwU2JUNm43RmU1RUhZVlpuWFZIaHozdXh4anY3UnFjTWl4UjJ6OG5vV1RTbjJEclRhYWhlbVIyR084dVk4SW9FSFNDcFQ3?oc=5","date":"2024-07-08","type":"trial","source":"PR Newswire","summary":"Capital Health Partnering with TVAX Biomedical to Offer Brain Cancer Immunotherapy Trial - PR Newswire","headline":"Capital Health Partnering with TVAX Biomedical to Offer Brain Cancer Immunotherapy Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQaE9pVFhQS3p0a1dQVGlnLWphV1VaQWN1UkJiWmxCNFpoNnNFQUNub1RRRU5MS0h6aU5iX3o2SjcwX1BHWk4wM01vNW5zbjJVUHZYWTMwOG1abTFfQlJSd2N3MERKQ0VuUUZfaW9DTXRDVDZSUkFGSHU1R0RzLTVQSjlFN2cyRFVnRTh5Zl9jeEdFbW81dFJ1YjVHUThWbUFpV2RN?oc=5","date":"2024-01-17","type":"pipeline","source":"The Business Journals","summary":"KC execs face costly realities of leading life sciences startups - The Business Journals","headline":"KC execs face costly realities of leading life sciences startups","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}